Colorectal cancer - Increased multidimensional understanding of the molecular genesis

Current Cancer Therapy Reviews

Volumn 4, Issue 4, 2008, Pages 243-252

  Søreide, Kjetil ^a   Thorsen, Kenneth ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Carcinogenesis; Colorectal cancer; Extracellular matrix; Genomic instability; Microsatellite instability; Precursor

Indexed keywords

DNA;

CANCER CELL; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOMAL INSTABILITY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONNECTIVE TISSUE; EARLY DIAGNOSIS; EXTRACELLULAR MATRIX; GENE SILENCING; GENOMICS; HUMAN; IMMUNE SYSTEM; INTESTINE CRYPT; METASTASIS; MICROSATELLITE INSTABILITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE;

EID: 65649104496     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408786413362     Document Type: Review

References (151)

1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005; 365: 153-65.
2. Søreide K, Nedrebø BS, Knapp J-C, et al. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol 2008; accepted
3. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-30.
4. Hajdu SI. Greco-Roman thought about cancer. Cancer 2004; 100: 2048-51.
5. Hajdu SI. Thoughts about the cause of cancer. Cancer 2006; 106: 1643-49.
6. Nordenstam JF, Bulander RE, Mellgren A, Rothenberger DA. Evolution of surgery for colorectal cancer. In Gillison W, Buchwald H (Eds): Pioneers in Surgical Gastroenterology, Edition Shrewsbury, UK: tfm Publishing Ltd. 2007.
7. Dukes C. Simple tumours of the large intestine and their relation to cancer. Br J Surg 1926; 13: 720.
8. Lockhart-Mummery J, Dukes C. The precancerous changes in the rectum and colon. Surg Gynecol Obstet 1928; 46: 591-96.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
10. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
11. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-37.
12. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-19.
13. Parsons R, Li GM, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75: 1227-36.
14. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-21.
15. Søreide K, Janssen EA, Søiland H, et al. Microsatellite instability in colorectal cancer. Br J Surg 2006; 93: 395-406.
16. Lynch HT, Lynch JF, Lynch PM. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J Natl Cancer Inst 2007; 99: 261-63.
17. Kwak EL, Chung DC. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer 2007; 6: 340-44.
18. Boland CR. Decoding hereditary colorectal cancer. N Engl J Med 2006; 354: 2815-17.
19. Bartlett S. Predictive model for hereditary colorectal cancer. Lancet Oncol 2006; 7: 624.
20. Baglietto L, Jenkins MA, Severi G, et al. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006; 59: 114-24.
21. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42: 216-27.
22. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
23. Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer 2007; 120: 664-71.
24. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 2006; 119: 2657-64.
25. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006; 27: 1301-09.
26. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
28. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-58.
29. Lotfi AM, Spencer RJ, Ilstrup DM, Melton LJ, 3rd. Colorectal polyps and the risk of subsequent carcinoma. Mayo Clin Proc 1986; 61: 337-43.
30. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma - carcinoma sequence in large bowel. Lancet 1978; 1: 245-47.
31. Morson B. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974; 67: 451-47.
32. Thiis-Evensen E, Hoff GS, Sauar J, et al. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414-20.
33. Hoff G, Sauar J, Vatn MH, et al. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol 1996; 31: 1006-10.
34. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
35. O'Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98: 371-79.
36. Citarda F, Tomaselli G, Capocaccia R, et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812-15.
37. Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334: 82-7.
38. Shimoda T, Ikegami M, Fujisaki J, et al. Early colorectal carcinoma with special reference to its development de novo. Cancer 1989; 64: 1138-46.
39. Jass JR. Do all colorectal carcinomas arise in preexisting adenomas? World J Surg 1989; 13: 45-51.
40. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277-84.
41. Bedenne L, Faivre J, Boutron MC, et al. Adenoma - carcinoma sequence or "de novo" carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers. Cancer 1992; 69: 883-8.
42. Kudo S, Tamura S, Hirota S, et al. The problem of de novo colorectal carcinoma. Eur J Cancer 1995; 31A: 1118-20.
43. Hermanek P, Gall FP. Early (microinvasive) colorectal carcinoma. Pathology, diagnosis, surgical treatment. Int J Colorectal Dis 1986; 1: 79-84.
44. Mueller JD, Bethke B, Stolte M. Colorectal de novo carcinoma: a review of its diagnosis, histopathology, molecular biology, and clinical relevance. Virchows Arch 2002; 440: 453-60.
45. Muto T, Nagawa H, Watanabe T, et al. Colorectal carcinogenesis: historical review. Dis Colon Rectum 1997; 40: S80-5.
46. Alrawi SJ, Schiff M, Carroll RE, et al. Aberrant crypt foci. Anti-cancer Res 2006; 26: 107-19.
47. Kudo S, Hirota S, Nakajima T, et al. Colorectal tumours and pit pattern. J Clin Pathol 1994; 47: 880-5.
48. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307: 1904-09.
49. Leedham SJ, Schier S, Thliveris AT, et al. From gene mutations to tumours - stem cells in gastrointestinal carcinogenesis. Cell Prolif 2005; 38: 387-405.
50. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
51. Boman BM, Walters R, Fields JZ, et al. Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol 2004; 165: 1489-98.
52. Preston SL, Wong WM, Chan AO, et al. Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003; 63: 3819-25.
53. Søreide K. Telomerase and Survivin in Colorectal and Pancreatic Cancer - biomarkers of life and death in the balance between proliferation and apoptosis. Curr Cancer Therapy Rev 2008; in press.
54. Wright NA, Poulsom R. Top down or bottom up? Competing management structures in the morphogenesis of colorectal neoplasms. Gut 2002; 51: 306-8.
55. Brabletz T, Hlubek F, Spaderna S, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65.
56. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002; 80: 105-10.
57. Heslin MJ, Yan J, Johnson MR, et al. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001; 233: 786-92.
58. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000; 36: 1258-68.
59. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006; 42: 728-34.
60. Søreide K, Janssen EA, Kørner H, Baak JP. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 2006; 209: 147-56.
61. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-17.
62. Søreide K. Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia. Scand J Gastroenterol 2008; 1-8.
63. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-49.
64. Søreide K. Genetics and molecular classification of colorectal cancer. Tidsskr Nor Laegeforen 2007; 127: 2818-23.
65. Watson AJ. Apoptosis and colorectal cancer. Gut 2004; 53: 1701-09.
66. Søreide K, Buter TC, Janssen EA, et al. Cell-cycle and apoptosis regulators (p16INK4A, p21CIP1, beta-catenin, survivin, and hTERT) and morphometry-defined MPECs predict metachronous cancer development in colorectal adenoma patients. Cell Oncol 2007; 29: 301-13.
67. Søreide K. Bacterial genotoxins, gene methylation and RNA interference: pointing to colorectal cancer as an infectious disease? Scand J Gastroenterol 2008; accepted.
68. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-38.
69. Leslie A, Pratt NR, Gillespie K, et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res 2003; 63: 4656-61.
70. Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-86
71. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5: 773-85.
72. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; 3: 695-701.
73. Woodford-Richens KL, Rowan AJ, Gorman P, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci U S A 2001; 98: 9719-23.
74. Kim H, Nam SW, Rhee H, et al. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004; 23: 6218-25.
75. Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132: 127-38.
76. Gerlach U, Kayser G, Walch A, et al. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer. J Pathol 2006; 208: 462-72.
77. Dunican DS, McWilliam P, Tighe O, et al. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 2002; 21: 3253-57.
78. Engelhardt M, Drullinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997; 3: 1931-41.
79. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004; 113: 160-68.
80. Rosa J, Canovas P, Islam A, et al. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006; 17: 1483-93.
81. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-15.
82. Dohi T, Altieri DC. Mitochondrial dynamics of survivin and "four dimensional" control of tumor cell apoptosis. Cell Cycle 2005; 4: 21-3.
83. Choi SW, Lee KJ, Bae YA, et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 2002; 8: 2311-22.
84. Giaretti W, Rapallo A, Sciutto A, et al. Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 2000; 21: 49-57.
85. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3: 83-8.
86. Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002; 123: 1109-19.
87. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123: 862-76.
88. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol 2002; 17: 17-26.
89. Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol 1998; 15: 126-30.
90. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
91. Liu B, Farrington SM, Petersen GM, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995; 1: 348-52.
92. Meijer GA, Hermsen MA, Baak JP, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 1998; 51: 901-9.
93. Postma C, Hermsen MA, Coffa J, et al. Chromosomal instability in flat adenomas and carcinomas of the colon. J Pathol 2005; 205: 514-21.
94. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994; 54: 1645-48.
95. de la Chapelle A. Microsatellite instability. N Engl J Med 2003; 349: 209-10.
96. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32.
97. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560-70.
98. Schoen RE. The case for population-based screening for colorectal cancer. Nat Rev Cancer 2002; 2: 65-70.
99. Furlan D, Casati B, Cerutti R, et al. Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J Pathol 2002; 197: 603-9.
100. Søreide K. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers - ready for prime time? Tumour Biol 2007; 28: 290-300.
101. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
102. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95: 6870-75.
103. Miyakura Y, Sugano K, Akasu T, et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol 2004; 2: 147-56.
104. Wheeler JM, Loukola A, Aaltonen LA, et al. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers. J Med Genet 2000; 37: 588-92.
105. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004; 23: 29-39.
106. Mori Y, Yin J, Sato F, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004; 64: 2434-38.
107. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-62.
108. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003; 532: 39-49.
109. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
110. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64: 3014-21.
111. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96: 8681-86.
112. Lin SY, Yeh KT, Chen WT, et al. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep 2004; 11: 341-8.
113. Lind GE, Thorstensen L, Lovig T, et al. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 2004; 3: 28.
114. Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-2903.
115. Kuismanen SA, Holmberg MT, Salovaara R, et al. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000; 156: 1773-79.
116. Aquilina G, Hess P, Branch P, et al. A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc Natl Acad Sci U S A 1994; 91: 8905-09.
117. Perucho M. Microsatellite instability: the mutator that mutates the other mutator. Nat Med 1996; 2: 630-1.
118. Ward RL, Cheong K, Ku SL, et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003; 21: 3729-36.
119. Kim IJ, Kang HC, Park JH, et al. Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. Clin Cancer Res 2003; 9: 2920-5.
120. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 2001; 158: 1517-24.
121. Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004; 91: 1275-91.
122. Mori S, Ogata Y, Shirouzu K. Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 2004; 9: 322-9.
123. Fernandez-Peralta AM, Nejda N, Oliart S, et al. Significance of mutations in TGFBR2 and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability. Cancer Genet Cytogenet 2005; 157: 18-24.
124. Giatromanolaki A, Sivridis E, Stathopoulos GP, et al. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. Anticancer Res 2001; 21: 253-9.
125. Jansson A, Sun XF. Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 2002; 20: 811-6.
126. Katsumata K, Sumi T, Tomioka H, et al. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer. Int J Clin Oncol 2003; 8: 352-6.
127. Trojan J, Brieger A, Raedle J, et al. BAX and caspase-5 frameshift mutations and spontaneous apoptosis in colorectal cancer with microsatellite instability. Int J Colorectal Dis 2004; 19: 538-44.
128. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998; 17: 999-1007.
129. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17: 1364-74.
130. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
131. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-24.
132. Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003; 22: 1317-23.
133. Fukushima T, Mashiko M, Takita K, et al. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 2003; 22: 315-20.
134. Li F, Cao Y, Townsend CM, Jr., Ko TC. TGF-beta signaling in colon cancer cells. World J Surg 2005; 29: 306-11.
135. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-23.
136. Banerjea A, Ahmed S, Hands RE, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004; 3: 21.
137. Prall F, Duhrkop T, Weirich V, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35: 808-16.
138. Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 2004; 568: 275-82.
139. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-16.
140. Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469-75.
141. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-13.
142. Velayos FS, Lee SH, Qiu H, et al. The mechanism of microsatellite instability is different in synchronous and metachronous colorectal cancer. J Gastrointest Surg 2005; 9: 329-35.
143. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
144. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
145. Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol 2004; 11: 977-82.
146. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
147. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-72.
148. Cossio SL, Ashton-Prolla P, Bortolini MC, et al. Microsatellite instability testing in genetically heterogeneous populations. J Clin Oncol 2007; 25: 913-914.
149. Yu J, Mallon MA, Zhang W, et al. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res 2006; 12: 5104-11.
150. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
151. Søreide K, Slewa A, Stokkeland PJ, et al. Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance. Cancer 2008; in press.